https://upnexhealth.com/2026/07/31/peptide-therapy-fda-compounding-patient-safety/UPNEX HEALTHen2026-07-31T13:19:17+00:00Peptide Therapy Is Having a Regulatory Moment. Here’s What Patients Should Know Before the Hype Gets Louderpatient safety, telehealth, FDA, Patient Education, Biohacking, Wellness Industry, MOTs-C, Compounded Drugs, BPC-157, Semax, Drug Compounding, Business of Healthcare, Med Spas, TB-500, Peptide Therapy, Peptides, KPV, Epitalon, peptide therapy FDA, FDA peptide vote, compounded peptides, wellness clinics, peptide therapy risks, peptide safetyhttps://upnexhealth.com/wp-content/uploads/2026/07/chatgpt-image-jul-31-2026-09_13_45-am.png?w=150https://upnexhealth.com/2026/07/30/litfulo-vitiligo-phase-3-results/UPNEX HEALTHen2026-07-31T01:40:39+00:00An Oral Vitiligo Drug Just Hit a Major Phase 3 MilestoneHealthcare Innovation, Clinical Research, Patient Education, LITFULO vitiligo, Phase 3 vitiligo trial, nonsegmental vitiligo, vitiligo treatment, oral vitiligo drug, ritlecitinib vitiligo, Pfizer LITFULO, JAK Inhibitor, Dermatology, LITFULO, Ritlecitinib, Skin Health, Vitiligo, Autoimmune Disease, Pfizer, Phase 3 Trials, Repigmentationhttps://upnexhealth.com/wp-content/uploads/2026/07/istockphoto-1364097824-612x612-1.jpg?w=150